— Know what they know.
Not Investment Advice

VIR NASDAQ

Vir Biotechnology, Inc.
1W: +8.1% 1M: +3.6% 3M: +24.8% YTD: +85.9% 1Y: +91.0% 3Y: +34.6% 5Y: -71.5%
$11.57
+0.53 (+4.80%)
After Hours: $11.32 (-0.25, -2.12%)
Weekly Expected Move ±7.6%
$9 $10 $11 $11 $12
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 59 · $1.9B mcap · 130M float · 1.55% daily turnover · Short 65% of daily vol
Credit Risk of going bust: lower than 56% of companies Debt: 4.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99.4%), Vir Biotechnology, Inc. would be worth roughly what it owes.
Total debt $93.3M against a stock market value of $1.87B.
Distance to default 5.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $46.6M (short-term plus half of long-term), stock volatility 63.0%; Altman Z'' 2.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$1.0B -28.3% ▼
5Y CAGR: +1.8%
Total Liabilities
$238M -4.4% ▼
5Y CAGR: +3.3%
Shareholders Equity
$765M -33.5% ▼
5Y CAGR: +1.3%
Cash & Investments
$463M -48.9% ▼
5Y CAGR: -8.9%
Total Debt
$187M +90.9% ▲
5Y CAGR: +21.6%
Net Debt
-$47M +62.3% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$348M$849M$242M$223M$234M
Short-Term Investments$360M$1.6B$1.3B$682M$229M
Cash & ST Investments$708M$2.4B$1.5B$905M$463M
Net Receivables$773M$0$0$0$4M
Inventory$0$0$0$0$0
Other Current Assets$9M$59M$66M$137M$48M
Total Current Assets$1.6B$2.5B$1.6B$1.0B$514M
Property, Plant & Equip.$130M$188M$167M$123M$118M
Goodwill & Intangibles$50M$50M$40M$25M$25M
Long-Term Investments$201M$24M$105M$190M$315M
Other Non-Current Assets$10M-$228M$19M$18M$32M
Total Non-Current Assets$391M$283M$331M$356M$489M
Total Assets$2.0B$2.8B$1.9B$1.4B$1.0B
— Liabilities —
Accounts Payable$7M$6M$6M$5M$10M
Short-Term Debt$0$0$0$0$9M
Deferred Revenue$98M$16M$65M$13M$0
Other Current Liabilities$0$8M$9M$16M$74M
Total Current Liabilities$341M$511M$175M$120M$93M
Long-Term Debt$0$0$0$0$89M
Other Non-Current Liab.$25M$33M$40M$39M-$33M
Total Non-Current Liabilities$181M$213M$153M$129M$145M
Total Liabilities$522M$724M$329M$248M$238M
— Equity —
Common Stock$13K$13K$13K$14K$14K
Retained Earnings-$139M$377M-$238M-$760M-$1.2B
Accumulated OCI-$1M-$9M-$815K-$2M-$2M
Total Stockholders Equity$1.4B$2.1B$1.6B$1.2B$765M
Total Liabilities & Equity$2.0B$2.8B$1.9B$1.4B$1.0B
— Key Metrics —
Total Debt$137M$128M$125M$98M$187M
Net Debt-$210M-$721M-$117M-$125M-$47M
Total Investments$562M$1.6B$1.4B$872M$543M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms